Intellia bags first pharma CRISPR deal

Intellia Therapeutics LLC (Cambridge, Mass.) on Wednesday announced a deal with Novartis AG (NYSE:NVS; SIX:NOVN) that assures the biotech's runway for five years while leaving plenty of room for additional deals. In the first biotech-pharma deal for a CRISPR- Cas9 technology, Novartis received exclusive rights to use Intellia's gene-editing platform for ex vivo engineering

Read the full 541 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE